<DOC>
	<DOCNO>NCT01910181</DOCNO>
	<brief_summary>This open-label , multicenter study evaluate pharmacokinetics , safety efficacy vemurafenib Chinese participant BRAF V600 mutation-positive unresectable metastatic melanoma . Participants receive vemurafenib 960 milligram ( mg ) orally twice daily disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study Vemurafenib ( Zelboraf ) Chinese Participants With BRAF V600 Mutation-Positive Unresectable Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Chinese male female participant , great equal ( ≥ ) 18 year age Histologically confirm metastatic melanoma ( surgically unresectable Stage IIIC Stage IV , American Joint Committee Cancer ) Treatmentnaïve receive prior systemic treatment metastatic melanoma Positive BRAF V600 mutation result determine designated laboratory use Cobas 4800 BRAF V600 Mutation Test Measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 Previous allow chemotherapy , immunotherapy , radiation therapy must complete least 2 week prior study drug administration , associate toxicity must resolve ( less equal [ ≤ ] Grade 1 baseline ) Recovery effect major surgery ( exclude tumor biopsy baseline ) significant traumatic injury least 14 day first dose study treatment Adequate hematologic , renal , liver function define protocol Fertile men woman must use effective method contraception treatment ≥6 month completion treatment direct physician ( accordance local requirement ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy great ( &gt; ) 3 month Able swallow pill Active central nervous system ( CNS ) lesion ( radiographically unstable/symptomatic lesion ) , except participant treat stereotactic therapy surgery remain without evidence disease progression brain ≥3 month corticosteroid anticonvulsant therapy ≥3 week History know spinal cord compression carcinomatous meningitis Anticipated ongoing administration anticancer therapy administer study Active squamous cell carcinoma ( SCC ) excise yet adequately heal post excision Pregnant lactate woman Refractory nausea vomiting , malabsorption , external biliary shunt , significant small bowel resection would preclude adequate vemurafenib absorption Any follow within 6 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , serious cardiac arrhythmia require medication , uncontrolled hypertension , cerebrovascular accident transient ischemic attack , symptomatic pulmonary embolism Known clinically significant active infection History allogeneic bone marrow transplantation organ transplantation Previous malignancy within past 5 year adequately treat basal cell carcinoma SCC skin , melanoma insitu , carcinoma insitu cervix and/or curatively treat cancer participant currently diseasefree , malignancy participant continuously diseasefree least 5 year Previous treatment BRAF inhibitor ( sorafenib allow ) MEK inhibitor Participants one dose vemurafenib previous clinical trial Known human immunodeficiency virus ( HIV ) positivity acquire immune deficiency syndrome ( AIDS ) relate illness , hepatitis B virus hepatitis C virus ( HCV ) carrier ( hepatitis B surface antigenpositive , HCV antibodypositive ) Received investigational treatment within 4 week study drug start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>